Condition: Hepatic Cell Carcinoma · Sponsor: Shanghai Ruiliyuan Biotechnology Co., Ltd.
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to prior systematic treatments.
This description comes directly from the study's public registry record.
Wenjin Huang · 021-61049928 · huangwenjin@shhryz.com
Always discuss trial participation with your own doctor first.
| Zhongshan Hospital Affiliated to Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06515314